Literature DB >> 22426520

Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo.

Tran Duc Dung1, Hsien-Cheh Chang, Truong Viet Binh, Maw-Rong Lee, Chang-Hai Tsai, Fuu-Jen Tsai, Wei-Wen Kuo, Li-Mien Chen, Chih-Yang Huang.   

Abstract

Hepatocellular carcinoma is a common type of cancer that is usually associated with poor prognosis. In this study, we examined the in vitro and in vivo mechanisms of the traditional Vietnamese herb Zanthoxylum avicennae on the inhibition of HA22T human hepatocellular carcinoma cell proliferation. HA22T cells were treated with different concentrations of Zanthoxylum avicennae extracts (YBBEs) and analyzed with the MTT assay, western blot analysis, flow cytometry, siRNA transfection assays and co-immunoprecipitation assay. Additionally, the HA22T-implanted xenograft nude mouse model was applied to confirm the cellular effects. YBBEs showed a strong inhibition of HA22T cell viability in a dose-dependent manner and significantly reduced cell proliferation-related proteins as well as induced cell cycle arrest in the G2/M phase. Protein phosphatase 2A (PP2A) siRNA or okadaic acid totally blocked YBBE-mediated cell proliferation inhibition. In addition, an HA22T-implanted nude mouse model further confirmed that YBBEs inhibit HA22T tumor cell growth and downregulate the survival and cell cycle regulating proteins, as well as activate the PP2A protein. Our findings indicate that the inhibition of HA22T cell proliferation by YBBEs is mediated through PP2A activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426520     DOI: 10.3892/ijmm.2012.938

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

1.  Taiwanin E Induces Cell Cycle Arrest and Apoptosis in Arecoline/4-NQO-Induced Oral Cancer Cells Through Modulation of the ERK Signaling Pathway.

Authors:  Shih-Hao Wang; Hsi-Chin Wu; Khan Farheen Badrealam; Yueh-Hsiung Kuo; Yun-Peng Chao; Hsi-Hsien Hsu; Da-Tian Bau; Vijaya Padma Viswanadha; Yi-Hui Chen; Pei-Jei Lio; Chung-Jen Chiang; Chih-Yang Huang
Journal:  Front Oncol       Date:  2019-12-17       Impact factor: 6.244

2.  Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma.

Authors:  Hui-Feng Chen; Jian-Rong Mai; Jian-Xin Wan; Yan-fang Gao; Li-Na Lin; Song-Zi Wang; Yu-Xi Chen; Chen-Zi Zhang; Yu-Jing Zhang; Bin Xia; Kun Liao; Yu-Chun Lin; Zhong-Ning Lin
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

Review 3.  PP2A-Mediated Anticancer Therapy.

Authors:  Weibo Chen; Zhongxia Wang; Chunping Jiang; Yitao Ding
Journal:  Gastroenterol Res Pract       Date:  2013-11-07       Impact factor: 2.260

Review 4.  Dietary Natural Products for Prevention and Treatment of Liver Cancer.

Authors:  Yue Zhou; Ya Li; Tong Zhou; Jie Zheng; Sha Li; Hua-Bin Li
Journal:  Nutrients       Date:  2016-03-10       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.